Skip to main content

CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60

The CDC panel's recommendation moves the U.S. closer to making the respiratory syncytial virus shots from Pfizer and GSK available to seniors.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.